This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
Vaxcyte Inc (NASDAQ:PCVX) is Needham’s top pick for 2023 and has been added to the Needham Conviction list and…
Needham Maintains Buy on Vaxcyte, Raises Price Target to $58
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $52 to $58.
SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60
SVB Leerink analyst David Risinger initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Outperform rating and announces Price Target of $60.
Guggenheim Initiates Coverage On Vaxcyte with Buy Rating, Announces Price Target of $66
Guggenheim analyst Seamus Fernandez initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Buy rating and announces Price Target of $66.
Vaxcyte Q3 EPS $(0.93) Down From $(0.51) YoY
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(0.93) per share. This is a 82.35 percent decrease over losses of $(0.51) per share from the same period last year.
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Vaxcyte Announces Pricing Of $600M Public Offering Of 15M Shares Of Common Stock At A Price Of $32/Share
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday.